Steven Boyd

Discovers, develops and commercializes pharmaceutical therapeutic products

York is a global, event-driven investment firm which specializes in M&A transactions, distressed situations, restructuring opportunities and special situations including spin-offs and split-ups, litigation opportunities, shareholder agitation and proxy contests, balance sheet arbitrage and consolidations. The firm seeks to generate consistent superior investment results relatively independent of the returns generated by the overall equity markets. Their approach is opportunistic and builds portfolios from the bottom-up on a trade-by-trade basis in response to market conditions.

Provides investment advice

Operates as a pharmaceutical company that develops and commercializes therapies for the treatment of ophthalmic diseases

Discovers and develops novel antibiotics

Operates as a management consulting firm

Senator pursues a global and opportunistic strategy for investing in distressed debt, value equities and event equities. They also pursue a global and opportunistic strategy for investing in “less-than-liquid” situations, including private or illiquid debt and equity investments. The firm emphasizes capital preservation and seeks to mitigate risk. Their allocation of capital depends upon where it believes the most attractive risk-adjusted opportunities exist.

Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases

Armistice seeks to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing primarily in equity securities, equity-related instruments, debt investments, and other assets. The firm typically employs a bottom-up analysis, assessing all components of the company’s capital structure.